Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model

Molecular Medicine Reports

Volumn 14, Issue 4, 2016, Pages 3277-3284

  Yang, Weiwei ^a   She, Liping ^b   Yu, Kun ^a   Yan, Shan ^a   Zhang, Xuefeng ^a   Tian, Xiaoyi ^a   Ma, Shuren ^a   Zhang, Xiwen ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Jiangsu Province Geriatric Hospital   (China)

Author keywords

Hepatic steatosis; Hyperlipidemia; Jatrorrhizine hydrochloride; Lipid metabolism; Liver

Indexed keywords

FAS ANTIGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; JATRORRHIZINE; JATRORRHIZINE HYDROCHLORIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; BERBERINE; LIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CPT1A GENE; DOWN REGULATION; DRUG EFFECT; FAS GENE; FATTY LIVER; GENE; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE; HYPERLIPIDEMIA; IN VIVO STUDY; INSULIN SENSITIVITY; LIPID DIET; LIPID OXIDATION; LIPOGENESIS; MALE; MOUSE; NONHUMAN; OBESITY; PPAR ALPHA GENE; SREBP 1C GENE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; CHEMISTRY; COMPLICATION; COPTIS; DRUG EFFECTS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; LIPID METABOLISM;

ANIMALS; BERBERINE; BODY WEIGHT; COPTIS; DIET, HIGH-FAT; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; LIPID METABOLISM; LIPIDS; MALE; MICE; MICE, INBRED C57BL; OBESITY; TRIGLYCERIDES;

EID: 84988473960     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5634     Document Type: Article

References (46)

1. Betteridge DJ: Diabetic dyslipidaemia. Eur J Clin Invest 29 (Suppl 2): S12-S16, 1999.
2. Goldberg IJ: Clinical review 124: Diabetic dyslipidemia: Causes and consequences. J Clin Endocrinol Metab 86: 965-971, 2001.
3. Lin J, Yang R, Tarr PT, Wu PH, Handschin C, Li S, Yang W, Pei L, Uldry M, Tontonoz P, et al: Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell 120: 261-273, 2005.
4. Mendelson JH and Mello NK: Alcohol-induced hyperlipidemia and beta lipoproteins. Science 180: 1372-1374, 1973.
5. Dunn FL: Hyperlipidemia in diabetes mellitus. Diabetes Metab Rev 6: 47-61, 1990.
6. Karthick N, Dillara K, Poornima KN and Subhasini AS: Dyslipidaemic changes in women with subclinical hypothyroidism. J Clin Diagn Res 7: 2122-2125, 2013.
7. Borba EF and Bonfá E: Dyslipoproteinemias in systemic lupus erythematosus: Influence of disease, activity, and anticardiolipin antibodies. Lupus 6: 533-539, 1997.
8. Sentí M, Romero R, Pedro-Botet J, Pelegrí A, Nogués X and Rubiés-Prat J: Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 41: 1394-1399, 1992.
9. O'Keefe JH and Bell DS: Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 100: 899-904, 2007.
10. Haffner SM: Diabetes, hyperlipidemia, and coronary artery disease. Am J Cardiol 83: 17F-21F, 1999.
11. O'Brien T, Nguyen TT and Zimmerman BR: Hyperlipidemia and diabetes mellitus. Mayo Clin Proc 73: 969-976, 1998.
12. Farnier M and Davignon J: Current and future treatment of hyperlipidemia: The role of statins. Am J Cardiol 82: 3J-10J, 1998.
13. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E and Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98: 2088-2093, 1998.
14. Garg A and Grundy SM: Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 264: 723-726, 1990.
15. Ast M and Frishman WH: Bile acid sequestrants. J Clin Pharmacol 30: 99-106, 1990.
16. Akoglu H, Yilmaz R, Kirkpantur A, Arici M, Altun B and Turgan C: Combined organ failure with combination antihyperlipidemic treatment: A case of hepatic injury and acute renal failure. Ann Pharmacother 41: 143-147, 2007.
17. Thompson PD, Clarkson P and Karas RH: Statin-associated myopathy. JAMA 289: 1681-1690, 2003.
18. Miettinen TA, Taskinen MR, Pelkonen R and Nikkilä EA: Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid. Acta Med Scand 186: 247-253, 1969.
19. Ho YP, To KK, Au-Yeung SC, Wang X, Lin G and Han X: Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety. J Med Chem 44: 2065-2068, 2001.
20. Hsu CL, Wu CH, Huang SL and Yen GC: Phenolic compounds rutin and o-coumaric acid ameliorate obesity induced by high-fat diet in rats. J Agric Food Chem 57: 425-431, 2009.
21. Park SH, Ko SK, Choi JG and Chung SH: Salicornia herbacea prevents high fat diet-induced hyperglycemia and hyperlipidemia in ICR mice. Arch Pharm Res 29: 256-264, 2006.
22. Chang XX, Yan HM, Xu Q, Xia MF, Bian H, Zhu TF and Gao X: The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet. Lipids Health Dis 11: 86, 2012.
23. Feng Q, Gou XJ, Meng SX, Huang C, Zhang YQ, Tang YJ, Wang WJ, Xu L, Peng JH and Hu YY: Qushi huayu decoction inhibits hepatic lipid accumulation by activating AMP-Activated protein kinase in vivo and in vitro. Evid Based Complement Alternat Med 2013: 184358, 2013.
24. Khin-Maung-U, Myo-Khin, Nyunt-Nyunt-Wai, Aye-Kyaw and Tin-U: Clinical trial of berberine in acute watery diarrhoea. Br Med J (Clin Res Ed) 291: 1601-1605, 1985.
25. Akhter MH, Sabir M and Bhide NK: Anti-inflammatory effect of berberine in rats injected locally with cholera toxin. Indian J Med Res 65: 133-141, 1977.
26. Amin AH, Subbaiah TV and Abbasi KM: Berberine sulfate: Antimicrobial activity, bioassay, and mode of action. Can J Microbiol 15: 1067-1076, 1969.
27. Lin CC, Ng LT, Hsu FF, Shieh DE and Chiang LC: Cytotoxic effects of Coptis chinensis and Epimedium sagittatum extracts and their major constituents (berberine, coptisine and icariin) on hepatoma and leukaemia cell growth. Clin Exp Pharmacol Physiol 31: 65-69, 2004.
28. Fu Y, Hu B, Tang Q, Fu Q, Zhang Q and Xiang JZ: Effect of jatrorrhizine, berberine, Huanglian Decoction and compound-mimic prescription on blood glucose in mice. Chung Tsao Yao Tsa Chih Pien Chi Pu 36: 548-551, 2005 (In Chinese).
29. Wu H, He K, Wang Y, Xue D, Ning N, Zou Z, Ye X, Li X, Wang D and Pang J: The antihypercholesterolemic effect of jatrorrhizine isolated from Rhizoma Coptidis. Phytomedicine 21: 1373-1381, 2014.
30. Fu Y, Hu B, Tang Q, Fu Q and Xiang J: Hypoglycemic activity of jatrorrhizine. J Huazhong Univ Sci Technolog Med Sci 25: 491-493, 2005.
31. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
32. Saltiel AR and Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799-806, 2001.
33. Kopelman PG: Obesity as a medical problem. Nature 404: 635-643, 2000.
34. Toth PP: Cardiology patient page. The 'good cholesterol': High-density lipoprotein. Circulation 111: e89-e91, 2005.
35. Wiegman CH, Bandsma RH, Ouwens M, van der Sluijs FH, Havinga R, Boer T, Reijngoud DJ, Romijn JA and Kuipers F: Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin. Diabetes 52: 1081-1089, 2003.
36. Liu F, Li Z, Shi X and Zhong M: Determination of berberine, palmatine and jatrorrhizine in rabbit plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Pharm Biomed Anal 56: 1006-1015, 2011.
37. Kong W, Zhao Y, Xiao X, Jin C, Liu Y and Li Z: Comparison of anti-bacterial activity of four kinds of alkaloids in Rhizoma Coptidis based on microcalorimetry. Zhongguohuaxue (yingwenban) 27: 1186-1190, 2009 (In Chinese).
38. Liu R, Cao Z, Pan Y, Zhang G, Yang P, Guo P and Zhou Q: Jatrorrhizine hydrochloride inhibits the proliferation and neovascularization of C8161 metastatic melanoma cells. Anticancer Drugs 24: 667-676, 2013.
39. Xiong C and Fang D: Effects of jatrorrhizine on isolated guinea pig atria. Zhongguo Yaolixue Yu Dulixue Zazhi 4: 255-259, 1989 (In Chinese).
40. Reddy JK and Rao MS: Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 290: G852-G858, 2006.
41. Renner EL and Dällenbach A: Increased liver enzymes: What should be done? Ther Umsch 49: 281-286, 1992 (In German).
42. Nguyen P, Leray V, Diez M, Serisier S, Le Bloc'h J, Siliart B and Dumon H: Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl) 92: 272-283, 2008.
43. Eberlé D, Hegarty B, Bossard P, Ferré P and Foufelle F: SREBP transcription factors: Master regulators of lipid homeostasis. Biochimie 86: 839-848, 2004.
44. Janani C and Ranjitha Kumari BD: PPAR gamma gene-A review. Diabetes Metab Syndr 9: 46-50, 2015.
45. Pawlak M, Lefebvre P and Staels B: Molecular mechanism of PPAR action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol 62: 720-733, 2015.
46. Wakil SJ and Abu-Elheiga LA: Fatty acid metabolism: Target for metabolic syndrome. J Lipid Res 50 (Suppl): S138-S143, 2009.